Ulinastatin inhibits liver metastasis from breast cancer in mice through CCL17/CCL22–CCR4 pathway

印国兵

doi:10.19401/j.cnki.1007-3639.2018.04.002

您当前的位置：

首页 >

文章列表页 >

Ulinastatin inhibits liver metastasis from breast cancer in mice through CCL17/CCL22–CCR4 pathway

更新时间：2026-01-27

- Ulinastatin inhibits liver metastasis from breast cancer in mice through CCL17/CCL22–CCR4 pathway
- China Oncology Vol. 28, Issue 4, Pages: 248-255(2018)
- 作者机构：
  
  重庆医科大学附属第二医院乳腺甲状腺外科,重庆,400010
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.04.002
  CLC： R737.9
- Published Online：12 June 2018，
  
  Published：12 June 2018
- 稿件说明：
移动端阅览
李霞,印国兵,程熙,等. 乌司他丁抑制CCL17/CCL22-CCR4介导的小鼠乳腺癌肝转移[J]. 中国癌症杂志, 2018, 28(4): 248-255.

印国兵. Ulinastatin inhibits liver metastasis from breast cancer in mice through CCL17/CCL22–CCR4 pathway[J]. China Oncology, 2018, 28(4): 248-255.
李霞,印国兵,程熙,等. 乌司他丁抑制CCL17/CCL22-CCR4介导的小鼠乳腺癌肝转移[J]. 中国癌症杂志, 2018, 28(4): 248-255. DOI： 10.19401/j.cnki.1007-3639.2018.04.002.

印国兵. Ulinastatin inhibits liver metastasis from breast cancer in mice through CCL17/CCL22–CCR4 pathway[J]. China Oncology, 2018, 28(4): 248-255. DOI： 10.19401/j.cnki.1007-3639.2018.04.002.

摘要

背景与目的：越来越多的研究表明趋化因子及其受体在癌症的发生、发展和转移中起关键作用。本文研究了乌司他丁（ulinastatin）对胸腺和活化调节趋化因子（thymus and activation-regulated chemokine，TARC）即CCL17/巨噬细胞来源的趋化因子（macrophage-derived chemokine，MDC）即CCL22-CC族趋化因子受体4（CC chemokine receptor 4，CCR4）信号通路介导的乳腺癌肝转移的影响及其作用机制。方法：通过小鼠乳腺脂肪垫（mfp）接种4T1乳腺癌细胞的方式构建小鼠乳腺癌模型，15 d后取小鼠乳腺肿瘤，并记录乳腺肿瘤的质量；采用免疫组织化学法检测乳腺肿瘤组织中CCR4及肝脏转移瘤中CCL22、CCL17蛋白的表达；采用慢病毒转染的方式抑制4T1乳腺癌细胞CCR4基因，采用蛋白质印迹法（Western blot）检测抑制效果，并以同样方式进行小鼠乳腺成瘤并观察肿瘤生长情况；用三种不同浓度乌司他丁处理4T1细胞荷瘤小鼠，15 d后采用免疫组织化学法检测乳腺癌组织中CCR4及肝脏组织中CCL22及CCL17的表达，采用Westernblot和实时荧光定量聚合酶链反应（real-time fluorescent quantitative polymerase chain reaction，RTFQ-PCR）分别检测肝脏组织中TGF-β的表达以及microRNA-34a和microRNA-31的含量，并进行TGF-β和microRNA-34a、microRNA-31、CCL22以及CCL17的相关性分析。结果：小鼠乳腺癌组织高表达CCR4，肝脏转移瘤高表达CCL22和CCL17；沉默4T1乳腺癌细胞CCR4的表达，可抑制乳腺癌成瘤性；乌司他丁抑制CCR4、TGF-β、CCL22、microRNA-31和CCL17的表达，促进microRNA-34a的表达。结论：乌司他丁具有抑制乳腺癌肝转移的作用，其具体机制可能与乌司他丁通过TGF-β-microRNA-34a-CCL22轴及microRNA-31-TGF-β-CCL17轴抑制肝乳腺癌；肝转移；乌司他丁；CCR4；CCL22；CCL17脏组织中与乳腺癌肝转移密切相关的CCL17/CCL22-CCR4信号通路有关。

Abstract

Background and purpose: Increasing evidences have shown the key roles of chemokines in the formation and metastasis of cancers. In this study

we investigated the molecular mechanisms of liver metastasis from breast cancer and the effects of ulinastatin on liver metastasis from breast cancer mediated by CCL17/CCL22–CCR4 pathway. Methods: A mouse xenograft model and corresponding control were established by subcutaneously inoculating 4T1 breast cancer cells into mouse mammary fat pad. Fifteen days later

the mice were sacrificed

and the breast tumors were weighed. Immunohistochemistry was performed to detect CCR4 protein expression in breast tumors and CCL22 and CCL17 protein expressions in liver metastasis. The CCR4 gene was found to be inhibited by lentiviral transduction in 4T1 breast cancer cells. Western blot was used to examine the inhibitory effect. The same method was used to induce breast tumorigenesis and to examine tumor growth. Three different concentrations of ulinastatin were used to treat 4T1 tumor-bearing mice. Fifteen days later

immunohistochemistry was used to assess the expression of CCR4 in breast tumors and the expression of CCL22 and CCL17 in liver tissues. Western blot and real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) were used to detect the expression of TGF-β

microRNA-34a and microRNA-31. We also analyzed the correlation between TGF-β and microRNA-34a

microRNA-31

CCL22

and CCL17. Results: Our results showed that CCR4 was highly expressed in mouse breast tumors. CCL22 and CCL17 were highly expressed in the liver metastasis. CCR4 expression was silenced in the 4T1 breast cancer cells and the in vivo growth of breast cancer xenograft tumor was inhibited. Ulinastatin significantly inhibited CCR4

TGF-β

CCL22

microRNA-31 and CCL17

but upregulated microRNA-34a. Conclusion: These results showed that ulinastatin can inhibit liver metastasis of breast cancer. The specific mechanism may involve ulinastatin acting on TGF-β-microRNA-34a-CCL22 and microRNA-31-TGF-β-CCL17 axes to inhibit CCL17/CCL22-CCR4 signaling pathway in liver tissues.

关键词

Keywords

references

Views

2402

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

A study of 30-year trends in incidence and mortality risks of breast cancer among young women in China

Impact of miR-193a-3p on migration and invasion of breast cancer stem cells through targeting TRIM14

Axillary management after neoadjuvant therapy for breast cancer and optimization of sentinel lymph node diagnosis and treatment

Related Author

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

LU Ye

ZHANG Wenxiang

KONG Xiangyi

FANG Yi

WANG Jing

GAO Jidong

Related Institution

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Shanghai Engineering Research Center of Artificial Intelligence Technology for Tumor Diseases

Department of Laboratory Medicine, Xingtai People’s Hospital

AI问答

⁰